Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888 Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888; these potential risks may also apply to other agents used in this study Breastfeeding should be discontinued if the mother is treated with indenoisoquinolines Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888 and SCH727965 Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with vorinostat Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with veliparib; this may also apply to other agents used in this study Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this drug Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN8237 Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD1775 (MK-1775) Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with XL184 Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN8237 and/or romidepsin Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD2171 Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with belinostat Patients who are nursing infants: breastfeeding should be discontinued if the mother is treated with the study agents Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dabrafenib Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ALT-803 Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with the study drugs Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pomalidomide Pregnant women are excluded from this study; breastfeeding should be discontinued prior to the mother being treated with the study drugs Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this agent Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN0128 (TAK-228) and ziv-aflibercept Pregnant or nursing women; breastfeeding should be discontinued if the mother is treated with MLN0128 Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with terameprocol Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with talazoparib (BMN 673) Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with GDC-0449 Breastfeeding should be discontinued if the mother is treated with sEphB4-HSA Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN0128 (TAK-228) Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with TRC102 Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IPdR Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with NT-I7 Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN0128 Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AT13387 and paclitaxel Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD9291 and necitumumab Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD9291 and navitoclax Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MEDI-570 Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with methoxyamine Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with erlotinib and onalespib Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with VX-970; these potential risks may also apply to other agents used in this study Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M6620 (VX-970) Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AT13387 (onalespib) Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with VX-970 Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M6620 (VX-970) and/or gemcitabine Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with VX-970 Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with VX-970; these potential risks also apply to the other agents used in this study, such as carboplatin and gemcitabine Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with any of these agents Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with high dose nelfinavir Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with SGI-110 Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dasatinib Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with selumetinib Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab and ipilimumab; these potential risks may also apply to blinatumomab Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MEDI4736 (durvalumab), tremelimumab and radiation Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ipilimumab Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab and/or bevacizumab Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with BAL101553 Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IPdR Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with PT2385